Cargando…

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review

Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but the efficacy is variable. Here, we report two pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yingxin, Cai, Yifeng, Chen, Jia, Cen, Jiannong, Zhu, Mingqing, Pan, Jinlan, Wu, Depei, Sun, Aining, Chen, Suning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542851/ https://www.ncbi.nlm.nih.gov/pubmed/34707996 http://dx.doi.org/10.3389/fonc.2021.753842

Ejemplares similares

Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World
por: Sun, Yingxin, et al.
Publicado: (2021)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11)
por: Sheng, Guangying, et al.
Publicado: (2017)

Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PCM1::JAK2 with erythroblastic sarcoma: a case report and literature review
por: Zhang, Lina, et al.
Publicado: (2023)

Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm
por: Kurian, Christine J., et al.
Publicado: (2020)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

Case Report: The Formation of a Truncated PAX5 Transcript in a Case of Ph-Positive Mixed Phenotype Acute Leukemia With dic(7;9)(p11-p13;p13)
por: Yu, Yan, et al.
Publicado: (2021)

The Role of New Technologies in Myeloproliferative Neoplasms
por: Palumbo, Giuseppe A., et al.
Publicado: (2019)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
por: Hermouet, Sylvie
Publicado: (2023)

Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms
por: Moia, Riccardo, et al.
Publicado: (2021)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)

A t(8;9)(p22;p24)/PCM1-JAK2 Translocation in a Patient With Myeloproliferative Neoplasm and Myeloid Sarcoma: First Report in Korea
por: Song, Ilgeun, et al.
Publicado: (2016)

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
por: Lim, Ken-Hong, et al.
Publicado: (2021)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
por: Pettersson, Helna, et al.
Publicado: (2023)

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
por: Goldin, Lynn R, et al.
Publicado: (2009)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
por: Paes, Jhemerson, et al.
Publicado: (2022)

P378: CHEMO-FREE TREATMENT OF VAF INDUCE A EARLY AND DEEP MOLECULAR RESPONSEIN IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA: A PROSPECTIVE, SINGLE ARM, PHASE II STUDY
por: LI, Mengyun, et al.
Publicado: (2023)

Myeloproliferative neoplasms – blurring the lines between cancer and chronic inflammatory disorder
por: Soyfer, Eli M., et al.
Publicado: (2023)

Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature
por: Giannotta, Juri Alessandro, et al.
Publicado: (2021)

A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm
por: Zhang, Haotian, et al.
Publicado: (2021)

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
por: Bellido, Mar, et al.
Publicado: (2012)

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
por: Čokić, Vladan P., et al.
Publicado: (2015)

The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms
por: Bahar, Burak, et al.
Publicado: (2016)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?
por: Anelli, Luisa, et al.
Publicado: (2018)

Two Cases of Severe Hypertension in JAK2 Mutation-Positive Myeloproliferative Neoplasms
por: Rao, Raunak, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j3sbh0qdqfdgubpq6633r32tlh